Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mid- to long-term multicenter study of a new regimen for retreated pulmonary tuberculosis
ChiCTR1900022890Phase 4Recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Feb 2019
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of moxifloxacin, rifabutin, prothionamide, pyrazinamide, ethambutol and 2 more in pulmonary tuberculosis (TB) (2 arms), sponsored by Shanghai Pulmonary Hospital. Primary endpoint: Cure rate. Started Feb 2019; status: recruiting.
02
Drugs
moxifloxacinrifabutinprothionamidepyrazinamideethambutol
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on ChiCTR1900022890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900022890.